Chugai and Taisho to Co-Develop and Market Antiresorptive Bisphosphonate R484.
Tokyo, Japan, Sept 13, 2006 - (JCN) - Chugai Pharmaceutical Co., Ltd. and Taisho Taishō (tī`shō), 1879–1926, reign name of emperor of Japan (1912–26). His given name was Yoshihito. The son of Mutsuhito, the Meiji emperor, he succeeded to the throne in 1912, but because of illness he played little part in governing the nation. Pharmaceutical Co., Ltd. have agreed to co-develop and market antiresorptive bisphosphonate bisphosphonate /bis·phos·pho·nate/ (bis-fos´fo-nat) diphosphonate. R484, (generic name: ibandronic acid) for treatment of osteoporosis in post-menopausal women.
Under the agreement, Chugai will receive an upfront fee and milestone payments from Taisho.
R484 is currently in phase II clinical trials in Japan and is expected to be the next generation osteoporosis treatment drug. It is marketed under the brand name Bonviva in the U.S.
Copyright [c] 2006 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2006 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion